Podium to Practice: Chicago 2026 – LUNG: CROWN study
OR
Studies / Trials Discussed
8502 – Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
8502 – Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.